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The therapeutic options for metastatic neuroendocrine tumors (NETs) are limited. As PI3K
signaling is often activated in NETs, we have assessed the effects of selective PI3Kp110α
inhibition by the novel agent BYL719 on cell viability, colony formation, apoptosis, cell cycle,
signaling pathways, differentiation and secretion in pancreatic (BON-1, QGP-1) and pulmo-
nary (H727) NET cell lines.
Methods
Cell viability was investigated by WST-1 assay, colony formation by clonogenic assay, apo-
ptosis by caspase3/7 assay, the cell cycle by FACS, cell signaling by Western blot analysis,
expression of chromogranin A and somatostatin receptors 1/2/5 by RT-qPCR, and chromo-
granin A secretion by ELISA.
Results
BYL719 dose-dependently decreased cell viability and colony formation with the highest
sensitivity in BON-1, followed by H727, and lowest sensitivity in QGP-1 cells. BYL719
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induced apoptosis and G0/G1 cell cycle arrest associated with increased p27 expression.
Western blots showed inhibition of PI3K downstream targets to a varying degree in the dif-
ferent cell lines, but IGF1R activation. The most sensitive BON-1 cells displayed a signifi-
cant, and H727 cells a non-significant, GSK3 inhibition after BYL719 treatment, but these
effects do not appear to be mediated through the IGF1R. In contrast, the most resistant
QGP-1 cells showed no GSK3 inhibition, but a modest activation, which would partially
counteract the other anti-proliferative effects. Accordingly, BYL719 enhanced neuroendo-
crine differentiation with the strongest effect in BON-1, followed by H727 cells indicated by
induction of chromogranin A and somatostatin receptor 1/2 mRNA-synthesis, but not in
QGP-1 cells. In BON-1 and QGP-1 cells, the BYL719/everolimus combination was synergis-
tic through simultaneous AKT/mTORC1 inhibition, and significantly increased somatostatin
receptor 2 transcription compared to each drug separately.
Conclusion
Our results suggest that the agent BYL719 could be a novel therapeutic approach to the
treatment of NETs that may sensitize NET cells to somatostatin analogs, and that if there is
resistance to its action this may be overcome by combination with everolimus.
Introduction
Neuroendocrine tumors (NET) are a heterogeneous group of malignancies. The therapy of
choice for limited non-metastatic disease is surgery, but therapeutic options of metastatic dis-
ease are limited, as recently reviewed [1]. Low to intermediate grade metastatic NET may be
managed by active surveillance, somatostatin analogs, loco-regional therapy, peptide receptor
radionuclide therapy (PRRT), chemotherapy or molecular targeted therapy. If they progress
and become more aggressive, chemotherapy shows only limited success (reviewed in [1]).
However, several important molecular pathways involved in the pathogenesis and progression
of NET have been identified to date, and open up new avenues for targeted therapies, includ-
ing the tyrosine kinase inhibitor (TKI) sunitinib [2] or the mTORC1 inhibitor everolimus
[3–5].
Besides the RAS/RAF/MEK/ERK or JNK pathways, one of the central signaling pathways is
the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mTOR sequence, which is frequently over-
activated in NETs [6–14].
In brief, PI3K—encoded by the PI3KCA gene—is activated by different receptor tyrosine
kinases (such as IGFR, EGFR, VEGFR, FGFR, RET) and in turn activates AKT which leads to
inhibition of TSC1/2 and consequently to disinhibition/activation of mTORC1/p70S6K, phos-
phorylation of 4EBP1, activation of eIF-4E, cell proliferation and tumor growth (analogous to
RAS/RAF/MEK/ERK signaling). RAS and PI3K may activate each other. Accordingly, the
mTORC1 inhibitor everolimus has shown significant efficacy in NETs in vitro, in vivo and in
clinical studies [1, 6], and has been approved for the treatment of pancreatic [5] and, very
recently, of gastrointestinal and lung NETs [3, 4]. However, mTORC1 inhibition leads to a
compensatory activation of PI3K/AKT signaling via p70S6K and IRS-1 activation, associated
with an increase in pAKTT308 (via PI3K/PDK1), pAKTS473 (via mTORC2) and RAS/RAF/
MEK/ERK signaling [15–19] (Fig 1). This compensatory up-regulation of PI3K/AKT and
RAS/RAF/MEK/ERK may cause tumor cell resistance of initially sensitive cells [18–26]. Thus,
PI3Kα inhibition in neuroendocrine tumor cells
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it could be speculated that PI3K inhibitors working more upstream may bypass this mecha-
nism of resistance and be more effective than mTORC1-inhibition alone. Indeed, different
panPI3K inhibitors (LY294002, BKM120) or the dual PI3K/mTORC1/2 inhibitor BEZ235
alone and in combination with mTORC1 inhibitors and a MEK inhibitor, respectively, have
shown anti-tumor potential in NET cells in vitro and in vivo [17, 18, 27–31]. In pancreatic
NET cells, a synergistic effect of everolimus plus BEZ235 has been reported [18]. However,
global clinical development of BEZ235—the most effective agent in pancreatic NET cells in
vitro [18]—has been terminated, and two clinical trials in pancreatic NETs were stopped early
due to poor tolerability, frequent treatment discontinuation, a non-fulfilled statistical endpoint
and, moreover, no clear superiority to everolimus [24]. However, selective inhibition of the
PI3Kα/110α-subunit—the predominant catalytic isoform in neuroendocrine pancreatic β-
cells [32] involved in glucose homeostasis regulation [33, 34] and angiogenesis [35]—may be
more effective and have a better safety profile than panPI3K inhibitors.
BYL719 is a selective PI3Kα inhibitor [36, 37] which has shown anti-proliferative activity in
the pancreatic NET cell lines BON-1 and QGP-1 in a recent study [18]. BON-1 cells were
more sensitive to BYL719 than QGP-1 cells in that study [18]. Notably, in pancreatic NET
cells, the selective PI3Kα inhibitor BYL719 led to an additional weak inhibition of mTORC1 at
10 μM; in contrast, the panPI3K inhibitor BKM120 did not induce supplementary mTORC1
inhibition. BKM120 plus everolimus was not synergistic, whereas BYL719 plus everolimus was
not tested in NET cells [18].
On the basis of that previous study, which showed anti-proliferative effects and partial
PI3K/mTORC1 inhibition in BON-1 and QGP-1 cells after BYL719 treatment [18], we have
now investigated the effects of the selective PI3Kα inhibitor BYL719 on pancreatic (BON-1,
QGP-1) and lung (H727) NET cells in detail. Besides exploring its influence on cell viability,
Fig 1. A: We treated cell lines with 9 different concentrations of BYL719 or vehicle control for 96 h and assessed cell viability with the
WST-1 assay (Roche). Viability of treated cells was stated in percent vs. control (mean ± standard deviation (SD)). Dose-response
curves and IC50 were calculated with GraphPad Prism software. B: In BON-1 and QGP-1 cells, colony formation was dose
dependently reduced down to 22% of vehicel controls, with IC50 values of 1,3 μM and 1,8 μM, respectively. Data are presented as
mean±SD of at least three independent experiments with five replicates per data point.
https://doi.org/10.1371/journal.pone.0182852.g001
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colony formation and PI3K/AKT/mTORC1/2-signaling, we also investigated the effects on
other signaling pathways, such as IGF1 and GSK3, assessing compensatory signaling pathway
activations and downstream targets; these included apoptosis, cell cycle, cell differentiation
[somatostatin receptor (SSTR)1/2/5 expression], chromogranin A (CgA) expression and secre-
tion. Moreover, we tested the combination treatment of BYL719 with everolimus in NET cell
lines, since additional mTORC1 inhibition has been shown to enhance sensitivity to BYL719
in breast cancer cells [38]. The aim of our study was to assess the efficacy of the PI(3)Kα inhibi-
tor BYL719 in different NET cell lines and to determine the underlying mechanisms of action
in order to explain the different cell line sensitivities, and to see if we could overcome partial
resistance via combination treatments. We hypothesized that BYL719 might be effective at
inhibiting the proliferation of NET cells to a different extent depending on cell line, and that
partial resistance may be overcome by combination treatments.
Our results showed for the first time that the selective PI3Kα or BYL719 led to GSK3 inhibi-
tion and induction of re-differentiation with a significant increase of SSTR1/2 transcription in
pancreatic BON-1 and pulmonary H727 cells associated with higher efficacy of BYL719 and
higher cell line sensitivity, compared to QGP-1 cells. In contrast, the lower sensitivity of QGP-
1 cells to BYL719 was associated with absent GSK3 inhibition and an absence of re-differentia-
tion; partial resistance to BYL719 could be overcome by combination with everolimus via
simultaneous PI3K/mTORC1 inhibition and hence strongly increased SSTR2 transcription.
Thus, BYL719 might be an effective therapy for NETs, especially in combination with everoli-
mus, and might sensitize NET cells to somatostatin analogs.
This study was a collaborative effort of five German research groups with complementary
expertise in preclinical studies on NET cell lines. The long-term goal is the establishment of a
preclinical collaborative network (NET-Z) that would provide an efficient and fast preclinical
evaluation of novel drug candidates for clinical trials.
Materials and methods
Cell lines and drugs
Pancreatic neuroendocrine tumor cell lines BON-1 [39] and QGP-1 [40] (both obtained from
Japanese Collection of Research Bioresources) and the typical bronchial carcinoid-NET cell
line NCI-H727 (H727) [41] (purchased from ATCC, Manassas, VA) underwent authentication
at the DSMZ (Braunschweig, Germany, in 2014), and their neuroendocrine features were con-
firmed by immunocytochemistry. Participating researchers received cell aliquots of the same
passage together with SOPs for culture procedures. Cell lines had been tested for PIK3CA
mutations by panel sequencing (Ion Seq Torrent Lung and Colon Panel v2). No PIK3CA
mutations had been detected. BYL719 is a selective PI3Kα inhibitor developed by Novartis
Pharma. All cell lines have been treated with different concentrations (10 nM– 250 μM) of
BYL719 (kindly provided by Novartis) versus DMSO control for several time periods accord-
ing to assay type. Everolimus was purchased from Selleckchem (Munich, Germany) and used
in concentrations between 1 and 10nM.
Cell viability
For determination of cell viability, the WST-1 Assay (Roche) was utilized according to the
manufacturer‘s instructions followed by calculation of IC50 and IC85. The relative IC50 and
IC85 values (indicating the concentration of half-maximal and 85% of maximal effect) were
determined by non-linear regression using GraphPad Prism 6 software (mean of three inde-
pendent experiments, 95% CI). Cells were incubated with 9 different concentrations of
BYL719 (1nM-250μM) against vehicle control for 96h. The procedure of experiments and
PI3Kα inhibition in neuroendocrine tumor cells
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analysis of results were conducted as described previously [42]. For statistical analysis, we
used Microsoft Excel and GraphPad Prism 6 analysis software (San Diego, Calif., USA). The
data passed a Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefors p value) for a
Gaussian distribution, appropriate for data sets below 20 data points. Outliers were identi-
fied by Grubbs’ test with α = 0.05. Dose-response curves were fitted to the measured data
using the method of least squares with variable slope; goodness of fit was quantified with R2
and sums of squares. For detection of significant differences between two or more data
groups, we used ANOVA followed by the Dunnett‘s test with a p value of <0.05. Data are
presented as mean±standard deviation (SD) of at least three independent experiments with
five replicates per data point.
For the combination experiments with BYL719/everolimus co-treatment, cell viability was
assessed by “Cell Titer 96 Aqueous One Solution” MTS cell viability assay (Promega, Madison,
WI, USA) according to the manufacturer‘s instructions as previously described in detail [43].
Cells were treated with various concentrations of 1 μM—20 μM BYL719, 1 nM -10 nM everoli-
mus, or a combination of both drugs for the indicated incubation times. The low dose combi-
nation experiments of 1 μM BYL719 plus 1 nM everolimus were conducted in Hamburg with
an incubation period of 120 h. The higher dose experiments were conducted in Munich with
an incubation period of 144 h. To identify potential synergistic or antagonistic effects between
BYL719 and everolimus on the natural logarithm of cell viability (ln cell viability), we used Lin-
ear Mixed Effects Models. BYL179, everolimus and the interactions between both were consid-
ered as fixed effects, the trial as a random effect. If a significant positive interaction between
BYL179 and everolimus on cell survival was found, we concluded an antagonistic effect; if a
significant negative interaction on cell survival was found, we concluded a synergistic effect.
One model was estimated for each cell line. Statistical significance was defined at p<0.05. All
computations were performed with R 3.2.2. For each MTS experiment, 4–6 independent sam-
ples per data point have been analyzed; each experiment was repeated at least two times in an
independent manner.
Colony formation
Soft agar colony formation assays were used for assessment of anchorage-independent growth,
as previously described [44]. Each experiment was repeated at least three times in an indepen-
dent manner.
Cell cycle
For flow cytometry analysis of the cell cycle, cells were seeded and incubated with two different
concentrations of BYL719 (IC50 and IC85 of the cell viability experiments for each cell line)
against vehicle control for 72h. Detailed conditions and procedure of treatment, staining, mea-
surement and analysis of results are described before [42]. DNA was stained with propidium
iodide and mitotic cells were detected with an antibody against phospho-Histon H3. For statis-
tical analysis, we used Microsoft Excel and GraphPad Prism 6 analysis software (San Diego,
Calif., USA). The data passed a Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefors
p value) for a Gaussian distribution, appropriate for data sets below 20 data points. Outliers
were identified by Grubbs’ test with α = 0.05. For detection of significant differences between
two or more data groups, we used ANOVA followed by the Dunnett‘s test with a p value of
<0.05. Data are presented as percentage of all detected cells (about 50.000 cells) (mean ± SD)
of at least four independent experiments.
PI3Kα inhibition in neuroendocrine tumor cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0182852 August 11, 2017 5 / 29
Apoptosis
Caspase activity/apoptotic activity was determined using the Apo-One homogeneous caspase-
3/7- Assay kit (Promega, #G7790): 10.000 cells per well were seeded, grown for 24 h and incu-
bated for 24 h with different concentrations of BYL719. Concentrations of 10 μM (effective
dose close to the IC50 of the cell viability experiments) and higher doses were tested. Caspase-
3/7 activity was assessed following the manufacturer’s instructions. For statistical analysis, a
priori tests evaluating the normal distribution and homogeneity of variances were performed
by the Kolmogorov-Smirnov-Test and the Levene0s Test of the SPSS statistical package SPSS
(version 13.0 for Windows, SPSS Inc (2005), Chicago, USA). Non-parametric criteria were
met; therefore, the Kruskal-Wallis followed by the Mann-Whitney test was performed. Statisti-
cal significance was assessed at p<0.05. Three independent samples per data point have been
analyzed; each experiment was repeated at least two times in an independent manner. The
results are displayed as mean ± SD.
Western blot technology
Western blot experiments were performed as previously described [45]. In brief, BON-1, H727
and QGP-1 cells were grown in 6-well plates for 24 h in complete medium. Afterwards, the
medium was replaced by fresh 10% FBS medium and the respective doses of BYL719, everoli-
mus or NVP-AEW541 were added for the respective incubation periods. In case of IGF1 stim-
ulation, cells were pre-treated with the respective drugs for 48 h followed by IGF1 stimulation
(50 ng/ml) for 30 minutes. After being washed twice in PBS, cells were lysed in 200 μl lysis
buffer (M-PER 1 Mammalian Protein Extraction Reagent containing HALT ™ protease &
phosphatase inhibitor cocktail, Thermo Scientific, Rockford, USA). Lysates were centrifuged
at 13,000 rpm for 10 min. Supernatants were adjusted to the same protein concentration (30–
50 μg/50 μl) (Rotiquant Universal, Carl Roth, Karlsruhe, Germany). Equal amounts of protein
were boiled for 5 minutes and denatured in Sodium dodecyl sulfate (SDS) sample buffer
(0.25% Tris HCL, 40% glycerol, 2% SDS, 1% dithiothreitol, bromophenol blue, pH 8.8) before
protein extracts were separated by SDS-PAGE and analysed by Western blot technology, as
described before in detail [45].
The following primary antibodies were utilized: Primary monoclonal antibodies against
pAKT (Ser473) (#4060), pAKT (Thr308) (#13038), AKT (#2920), pGSK3 (Ser21/9) (#8566),
GSK3 (#5676), pERK1/2 (Thr202/Tyr204) (#4370), pp70S6K (Thr389) (#9234), p70S6K
(#9202), pEGFR (Tyr1068) (#3777), EGFR (#4267), p4EBP1 (Ser65) (#9451), 4EBP1 (#9644),
pS6 (Ser240/4) (#5364), S6 (#2317), p27 Kip1 (#3686), Caspase 3 (#9662), PARP (#9542),
pChk1 (Ser345) (#2341), Chk1 (#2360), pRb (Ser780) (#9307), Cyclin D3 (#2936), pIGF1
(Tyr1131) (Tyr1146) (#3021), IGF1 (#3027) (all from Cell Signaling, Danvers, MA), Rb
(#614602) (Biolegend, San Diego, USA), p21 Waf1/Cip1 (610233) (from BD Transduction
Laboratories, Heidelberg, Germany), Actin (A5441) (Sigma, St. Louis, USA), Erk 1/2 (06–182)
(Merck-Millipore, Darmstadt, Germany), SSTR2 (Abcam, Cambrdige, UK), GAPDH (Clone
6C5, Merck-Millipore, Darmstadt, Germany).
Actin was used as loading control. Peroxidase-conjugated polyclonal secondary antibody
(1:25000) was incubated for 2 h, the blots were immersed in the chemiluminescent substrate
SuperSignal West Dura (Thermo Scientific, Rockford, USA) and images were taken with an
ECL Chemocam Imager (INTAS, Göttingen, Germany) or generated by using conventional
X-ray films. Optical density of the approximately sized bands was densitometrically quantified
using ImageJ 1.440 software (Wayne Rasband, National Institute of Health, USA). Band
intensities were quantified from at least 3 independent experiments for each cell line and pro-
tein, and are described as the mean percentage relative to the untreated control (100%). We
PI3Kα inhibition in neuroendocrine tumor cells
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performed statistical analysis according to the following method: A linear mixed effects model
was estimated for the logarithm of the relative increase [compared to the respective control
group] with the trial as random effect. The logarithm was chosen to account for the multiplica-
tive nature of the data. Analogously, means and standard deviations are reported as geometric
means and geometric standard deviations of the relative increase, respectively. A geometric
mean of "1.0" has to be interpreted as "equal to the control group" and for the geometric stan-
dard deviation “1.0” refers to “no variation“. We compared the phospho(p)-protein expression
to the control to adequately assess the extent of activation or inhibition of signaling pathways
after drug treatment and compare it between the different cell lines. All original uncropped
Western blots are shown as supplementary Figures (S1–S23, S29 and S30 Figs).
Gene expression analysis of somatostatin receptors (SSTR) 1/2/5 and
chromogranin A (CHGA)
For monotherapy with BYL719 we evaluated an effective dose close to the IC50 of the cell via-
bility experiments (10μM). For combination treatment we used concentrations that gave us a
synergistic effect at the lowest dose, therefore achieving maximum synergistic effects but mini-
mizing potential toxic side effects. Thus, tumor cells were treated for 96h with BYL719 at
10μM (monotherapy) or at 1μM BYL719 and 1nM everolimus (combination treatment). Total
RNA was isolated from cell cultures using the Nucleo Spin RNA, DNA and protein purifica-
tion Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s protocol. Total
RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) and a T3 Thermocycler (Biometra, Göttingen,
Germany).
We used pre-validated TaqMan Primers for SSTR1, SSTR2, SSTR3, SSTR5 and GAPDH for
real-time PCR. These primers were purchased from Applied Biosystems. Samples in duplicate
were subjected to PCR in a Step One Plus Real-Time PCR System (Applied Biosystems). Val-
ues were expressed as (Ct) values normalized to housekeeping gene GAPDH using the 2-ΔΔCt
method. All graphs and statistical analysis were performed using GraphPad Prism 4 utilizing
standard two-tailed unpaired Students t-test for normally distributed data. P-values <0.05
have been considered significant (<0.05; <0.005, <0.001). Data are presented as
mean ± standard error of mean (SEM) of at least three independent experiments with three
replicates per data point.
ChromograninA (CgA) ELISA
BON, H727 and QGP-1 cells were seeded in 24-well plates at a density of 2x105 per well and
grown for 24 h. Cells were treated with either 0.1% DMSO (vehicle control), PDBu (Phorbol-
12,13-dibutyrate; Sigma-Aldrich, Deisenhofen, Germany) as a positive control for the induc-
tion of secretion or BYL719 for 24 h in growth medium. Media were collected and remaining
cell debris was eliminated by centrifugation for 3 min at 200 x g. CgA concentration in the
supernatants was measured using CgAnalyze Kit (DAKO, Hamburg, Germany) according to
the manufacturer’s protocol. Two independent experiments with three replicates per data
point were analyzed.
Results
Cell viability, apoptosis and cell cycle
Significant reduction cell viability in NET cell lines in vitro. The pancreatic NET cell
lines BON-1 and QGP-1 and the typical bronchial carcinoid cell line H727 were treated with
PI3Kα inhibition in neuroendocrine tumor cells
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increasing doses of BYL719 for 96 h and cell viability was determined by the WST-1 assay.
BON-1 cells showed the highest sensitivity to BYL719 with an IC50 of 3.29 μM, followed by
H727 cells with an IC50 of 5.48 μM, and QGP-1 cells with the lowest sensitivity to BYL719 and
an IC50 of 17.57 μM (Fig 1A).
The IC85 was 100 μM in all cell lines (Fig 1A): 96 h treatment with low doses of 1 μM
BYL719 only led to a slight decrease in cell viability in all three cell lines (by 36%, 11% and 7%
in BON-1, H727 and QGP-1 cells, respectively) (Fig 1A).
Colony formation assay demonstrated the efficacy of BYL719 in pancreatic NET cells with
a higher sensitivity for BON-1 cells compared to QGP-1 cells. BYL719 dose-dependently
reduced colony formation down to 22% of vehicle controls, with IC50 values of 1.3 μM (BON-
1) and 1.8 μM (QGP-1) (Fig 1B). H727 cells did not form colonies.
Induction of apoptosis. Caspase 3 and 7 activity was measured by caspase3/7 assay after
24 h of treatment with increasing concentrations of BYL719: 10 μM and higher concentrations
of BYL719 significantly induced apoptosis in all 3 cell lines, BON-1, QGP-1 and H727 cells.
The strongest apoptosis induction was found in BON-1 cells, followed by H727 cells, with
QGP-1 showing the least but still significant apoptosis. The data shown represent the
mean ± SD (Fig 2).
Consistent with clear apoptosis induction, western blot analyses showed a dose-dependent
significant increase of cleaved caspase-3 and cleaved PARP in all three cell lines after 24 h of
treatment with BYL719 (S1 Table, Fig 3).
Cell cycle arrest in G0/G1. While p27 and p21 inhibit cell cycle progression by inhibition
of cyclin dependent kinases, Cyclin D3 induces cell cycle progression from G0/G1- to S-phase,.
Activation of the DNA-damage checkpoint marker CHK1 leads to cell cycle arrest, DNA-
repair and if ineffective cell death to prevent damaged cells from cell cycle progression.
Fig 2. Assessment of apoptosis: Caspase 3/7 assay results after 24 h treatment with different doses of BYL719 are
shown as mean percentage of caspase 3/7 activity referred to the untreated control (100%) ± SD: Strongest apoptosis
was induced in BON-1 cells, followed by H727 cells. QGP-1 cells showed the least but still significant apoptosis. * p<0.05; **
p0.01; *** p0.001 (two independent experiments with three replicates per data point).
https://doi.org/10.1371/journal.pone.0182852.g002
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Fig 3. Representative western blots of the investigated signaling pathways, apoptosis and cell cycle markers in
BON-1, QGP-1 and H727 cells: The means, standard deviations and p-values of the western blot quantification
and statistical analysis from at least three independent replicates are given in S1 Table.
https://doi.org/10.1371/journal.pone.0182852.g003
PI3Kα inhibition in neuroendocrine tumor cells
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BON-1, QGP-1 and H727 cells were treated with BYL719 for 72 h and changes in cell cycle
patterns were assessed by flow cytometry. BYL719 increased the G0/G1 fraction at IC50 concen-
trations indicating induction of G0/G1 cell cycle arrest. At higher doses (IC85), a sub-G1 frac-
tion suggested induction of cell death (Fig 4A).
Furthermore, the percentage of mitotic cells was assessed by mitotic index flow cytometry
(mitotic index: percentage of cells which are in the mitotic phase). In all three cell lines the per-
centage of mitotic cells decreased at high dose of BYL719 treatment (mean of four independent
experiments, including standard deviation) (Fig 4B).
Consistent with induction of G0/G1-cell cycle arrest, p27 was significantly increased after 24
h treatment in all three cell lines (S1 Table, Fig 3); the strongest up-regulation of p27 at 10–
20 μM BYL719 was found in BON-1 cells (S1 Table, Fig 3). Moreover, there was a non-signifi-
cant decrease of Cyclin D3 in all three cell lines, also promoting G0/G1-cell cycle arrest (S1
Table, Fig 3). According to the induction of apoptosis, as discussed below, there was a signifi-
cant reduction of the cell cycle regulator p21 in all three cell lines after 24 h treatment (S1
Table, Fig 3).
We observed a significant inhibition of the DNA damage checkpoint marker Chk1
(pChk1Ser345) after 24 h treatment in all three cell lines—in BON-1 cells at doses higher than
15 μM, in H727 and QGP-1 cells at all tested doses (S1 Table, Fig 3).
Signaling pathways
PI3K/AKT/mTORC1/2 and ERK signaling: Partial inhibition of PI3K/AKTSer473/Thr308,
mTORC1 and ERK signaling. Activated/phosphorylated (p)AKTSer473 indicates mTORC2-
dependent PI3K/AKT activity, while pAKTThr308, which is mediated by PDK1, is a marker
Fig 4. Cell lines were treated with BYL719 (IC50 and IC85) for 72 h. Cells were stained with PI (DNA
content) analysis solely included and mitosis-specific Phospho(Ser10)-Histone H3 immunostain followed by
flow cytometry assessment (single cells). According to the stain, events were divided into cells of several cell
cycle phases or were classified as sub-G1-events indicating cell death (FlowJo software), given in percent of
all detected cells (mean ± SD) of at least four independent experiments. A: Cell cycle. B: Mitotic index.
* p<0.05; ** p0.01; *** p0.001; **** p0.0001.
https://doi.org/10.1371/journal.pone.0182852.g004
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PI3K/PDK1/AKT activity; pp70S6K, pS6 and p4EBP1 are downstream-targets of mTORC1
and markers of mTORC1 activation; pERK displays activation of RAS/RAF/ERK signaling.
In BON-1 and QGP-1 cells, there was a significant inhibition of AKTSer473 at all tested
doses (10–40 μM) of BYL719 after 24 h treatment; a lower and inconsistent inhibition of
PI3K/AKTSer473 was seen in H727 cells with a statistical significance at doses higher than
15 μM (S1 Table, Fig 3). Similar results were found for PI3K/AKTThr308 with a significant inhi-
bition in QGP-1 cells at all tested doses and in BON-1 cells at doses higher than 15 μM. In con-
trast, in H727 cells there was a non-significant activation of PI3K/AKTThr308 (S1 Table, Fig 3).
In all three cell lines, mTORC1 was significantly inhibited after 24 h treatment with 10–40 μM
BYL719 as demonstrated by significant reduction of pp70S6K, pS6 and p4EBP1 (S1 Table, Fig
3). The strongest decrease of pp70S6K and pS6 was found in H727 cells, followed by QGP-1
cells, and the lowest, but a significant decrease was still observed in BON-1 cells. The decrease
of p4EBP1 was significant in H727 cells at all tested doses, but in BON-1 and QGP-1 cells only
at the highest tested dose (S1 Table, Fig 3); We observed a slight inhibition of ERK signaling
upon 24 h BYL719 treatment in all three cell lines with a statistical significance only at high
doses (at 20 μM in BON-1 and 40 μM in QGP-1 and H727 cells) (S1 Table, Fig 3).
Inhibition of GSK3 in BON-1 and H727 cells, but not in QGP-1 cells. The growth-fac-
tor-induced PI3K/AKT signaling pathway phosphorylates and thereby inhibits GSK3 [46–48].
In our study GSK3α and β (GSK3) behaved similarly. We quantified both together and sepa-
rately (S1 Table). Unexpectedly, despite significant PI3K/AKT inhibition after 24 h BYL719
treatment, there was a dose-dependent phosphorylation/inhibition of GSK3 in BON-1 and
H727 cells with a significant inhibition of GSKα/β and especially GSK3 in BON-1 cells at doses
higher than 10 μM (S1 Table, Fig 3); in QGP-1 cells, there was no inhibition, but a modest acti-
vation of GSK3 at doses higher than 10 μM BYL719 after 24 h treatment (S1 Table, Fig 3).
Additional Western blot analysis with low dose treatment of 1 μM BYL719 was performed in
the most sensitive cell line BON-1 as our cell line model: we showed no effects on pGSK3,
compared to the control (S24 Fig). PGSK3 was increased in BON-1 cells at 2.5 μM BYL719
and higher doses (S25 Fig).
Receptor tyrosine kinases: Strong activation of IGF1R signaling. Phosphorylated (p)
IGF1R and pEGFR are markers of activated receptor tyrosine kinases IGF1R and EGFR,
respectively. IGF1R may also phosphorylate/inhibit GSK3 [46–48]. In BON-1, QGP-1 and
H727 cells, IGF1R was significantly activated after treatment with 10–40 μM BYL719 for 24 h
with strongest activation in H727 cells, followed by BON-1 cells and lowest activation in QGP-
1 cells (S1 Table, Fig 3). Additional Western blot analysis after low dose treatment with 1 μM
BYL719 still showed IGF1R activation in BON-1 cells as our cell line model (S24 Fig).
EGFR activity was not notably altered in any cell line.
Combination treatment of BYL719 with the specific IGF1R inhibitor NVP-AEW541.
In order to prove a potential dependence of GSK3 phosphorylation on IGF1R activation in
response to BYL719 treatment, we tested co-treatment of BYL719 with the specific IGF1R
inhibitor NVP-AEW541 in all three cell lines for an incubation period of 48 h; surprisingly,
such co-treatment showed at least additive inhibitory effects on BON-1, H727 and QGP-1 cell
viability. We confirmed again that BYL719 led to phosphorylation/inhibition of GSK3 in
BON-1 and H727 cells. However, unexpectedly, this inhibitory effect on GSK3 was even
enhanced in both BON-1 and H727 cells by co-treatment with NVP-AEW541 (and not
blocked), being accompanied by stronger IGF1R phosphorylation/activation after combina-
tion treatment. In QGP-1 cells neither drug alone nor the combination changed GSK3 phos-
phorylation: in QGP-1 cells NVP-AEW541 alone inhibited IGF1R phosphorylation/activation
and co-treatment inhibited the BYL719-induced IGF1R activation. In QGP-1 and H727 cells
total IGF1R expression was slightly increased after NVP-AEW541 treatment alone. H727 cells
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showed a low baseline phosphorylation of the IGF1R. In BON-1 cells, which showed a very
low baseline phosphorylation/activation of IGF1R, NVP-AEW541 did not change phosphory-
lation or total expression levels of IGF1R (S26 Fig).
The low baseline phosphorylation/activity of the IGF1R in BON1 and H727 cells might not
have been sufficient to show the effects of specific IGF1R inhibition by NVP-AEW541; more-
over, others have shown a dependence of GSK3 phosphorylation on IGF1R activity in medul-
loblastoma cells [49], but they stimulated their cells with IGF1 to demonstrate clear results. We
therefore enhanced and optimized our experimental design by using IGF1 stimulation accord-
ing to the previously-published experimental design [49]. We used a slightly lower dose of
10 μM BYL719 because we expected a much stronger IGF1R phosphorylation after IGF1 stim-
ulation, and we wished to investigate if the absent effect of NVP-AEW541 on BYL719-induced
GSK3 phosphorylation could also be observed at lower doses of 10 μM BYL719. We could
then show strong baseline IGF1R phosphorylation/activity after IGF1 stimulation in all three
cell lines, which could be clearly inhibited by NVP-AEW541 in all three cell lines. As expected,
BYL719 led to strong IGF1R activation in all cell lines, and NVP-AEW541 prevented the
BYL719-induced IGF1R activation. However, while the baseline phosphorylation of GSK3
increased after stimulation with IGF1 in all three cell lines, it was even more strongly increased
after either NVP-AEW541 treatment or BYL719 treatment alone in BON-1 (especially GSK3β)
and H727 cells. In QGP-1 cells no changes in GSK3 phosphorylation after drug treatment
were seen, consistent with our previous results. Thus, despite IGF1R inhibition after combina-
tion treatment in all three cell lines, the phosphorylation/inhibition of GSK3 was even stronger
after the combination treatment in H727 cells and not changed in BON-1 and QGP-1 cells
compared to single BYL719 treatment (S27 Fig). Therefore, blockade of the IGF1R did not
attenuate BYL719-induced GSK3 phosphorylation refuting our initial hypothesis of the depen-
dence of BYL719-induced GSK3 phosphorylation on IGF1R activation in BON1 and H727
cells.
mRNA expression of NET markers (SSTR1, SSTR2, SSTR5, CHGA):
Induction of cell re-differentiation in BON-1 and H727 cells, but not in
QGP-1 cells
Treatment of cells with 10 μM BYL719 for 96 h induced mRNA expression of genes related to
neuroendocrine differentiation in BON-1 and H727 cells. Transcripts for CgA (CHGA),
SSTR1 and SSTR2 were induced in H727 and BON-1 cells, whereas SSTR5 was reduced. In par-
ticular, we observed a 2.5- (CI 1.8–3.1) and 4.5- (CI 2.6–6.3) fold induction of SSTR2 mRNA
upon BYL719 treatment in H727 and BON-1 cell, respectively (p<0.001). In contrast, in QGP-
1 cells SSTR1 transcripts were reduced, while CHGA, SSTR2 and SSTR5 were unaffected (Fig
5A). We also tested SSTR2 mRNA expression in all three cell lines after treatment with a low
dose of 1 μM BYL719 for 96 h and found significant SSTR2 induction in BON-1 and H727
cells, but not in QGP-1 cells.
CgA secretion was not altered
To evaluate the influence of BYL719-induced cell differentiation and signaling on CgA secre-
tion in neuroendocrine tumor cells, BON-1, H727 and QGP-1 cells were analyzed for their
release of CgA when treated with either vehicle, the known PKC activator and secretagogue
phorbol-12,13-dibutyrate (PDBu), or two concentrations of BYL719. As Fig 6 demonstrates,
PDBu at a concentration of 1 μM was able to increase the concentration of secreted CgA in
BON-1 cells from the basal value (366 ± 58 U/ml) about 5-fold (2061 ± 166 U/ml). PDBu also
raised CgA levels in the medium of H727 (about 2-fold) and QGP-1 cells (about 1.5-fold). In
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Fig 5. Neuroendocrine marker expression was increased by BYL719 treatment. A: BON-1, H727 and QGP-1 cells were treated with
10 μM BYL719 for 96 h and mRNA expression of Chromogranin A (CHGA), SSTR1, SSTR2 and SSTR5 was analyzed by qPCR. B: BON-1,
H727 and QGP-1 cells were treated with 1 μM BYL719 for 96 h and mRNA expression of SSTR2 was analyzed by qPCR; Values are
summarized from three independent experiments of three replicates per data point. * p<0.05; ** p0.01; *** p0.001.
https://doi.org/10.1371/journal.pone.0182852.g005
Fig 6. CgA secretion of NET cells was not altered by BYL719 treatment. BON-1, H727 and QGP-1 cells
were treated with vehicle, PDBu (positive control) or BYL719 (1 μM, 10 μM) for 24 h; the supernatant was
collected for CgA measurements (two independent experiments with three replicates per data point).
https://doi.org/10.1371/journal.pone.0182852.g006
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contrast, BYL719 did not alter the concentration of CgA in either BON-1, H727 or QGP-1 cell
supernatants at either 1 or 10 μM concentrations (Fig 6).
Synergistic effect of BYL719 plus everolimus in QGP-1 cells
Given earlier reports on synergistic effects of combination therapies with PI3K and mTOR
inhibitors, we evaluated the potential of co-treatment of BYL719 and everolimus in our NET
cell line models in vitro. In QGP-1 cells—showing the lowest sensitivity to BYL719 alone—a
synergistic inhibitory effect of 1–20 μM BYL719 plus 1–10 nM everolimus on cell viability was
found (p0.01) (Fig 7A).
In BON-1 cells, there was also a synergistic effect at low doses of 1 μM BYL719 plus 1 nM
everolimus, and an additive effect of both treatments at higher doses (Fig 7A), whereas H727
cells did not respond to everolimus and no synergistic or additive effect was observed in the
latter (data not shown). As described earlier, Western blot analysis showed a strong activation
Fig 7. A: The combination therapy of BYL719 plus everolimus was synergistic in QGP-1 cells at all tested doses (1–20 μM BYL719
plus 1–10 nM everolimus) and in BON-1 cells at low doses (1 μM BYL719 plus 1 nM everolimus) (p0.01), and additive in BON-1 cells
at higher doses. MTS cell viability assay data are shown as mean ± SD of 4–6 replicates per data point from two independent
experiments, referred to the untreated control; syn: synergistic (p0.01); add: additive; **, *** highly significant, compared to the
control (** p0.01, *** p0.001); B: Co-treatment of BON-1 and QGP-1 cells with BYL719 and everolimus prevented everolimus-
induced AKT activation. Cells have been treated with 5 μM BYL719, 5 nM everolimus or the combination of both for 48h and subjected
to western blot analysis of pAKTSer473, AKT and GAPDH. Representative Western Blot of three replicates.
https://doi.org/10.1371/journal.pone.0182852.g007
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of AKT after treatment with everolimus alone, which was almost completely prevented by
addition of a low dose of 5 μM BYL719 in BON-1 and QGP-1 cells (Fig 7B).
Moreover, 1 μM BYL719 plus 1 nM everolimus significantly more strongly induced SSTR2
transcription compared to each drug separately in BON-1 (12.5-fold, CI 5.8–19.2) and QGP-1
cells (1.5-fold, CI 1.2–1.7) (Fig 8).
It should be noted that this synergism already occurred at doses (1 μM for BYL719 and 1
nM for everolimus), which do not influence cell viability as monotherapies.
Comparison of BYL719 versus the panPI3K inhibitor BKM120 in BON-1
cells
To prove the involvement of other PI3K subunit isoforms apart from PI3Kα in NET signaling,
we compared the efficacy of the selective PI3Kα inhibitor BYL719 to the efficacy of the pan-
PI3K inhibitor BKM120 in the most sensitive cell line BON-1 cells as our model, and found a
much stronger inhibitory effect of BKM120 at low doses, compared to BYL719 (IC20 BKM120
at 72h 0.5 μM vs. IC20 BYL719 at 72 h 6.9 μM; IC50 BKM120 at 72 h 1.2 μM vs. IC50 BYL719 at
72 h not reached) (S28 Fig).
Discussion
Cell viability, apoptosis and cell cycle
BYL719 dose-dependently reduced NET cell viability and colony formation with highest sensi-
tivity for BON-1, followed by H727 cells and with the lowest sensitivity for QGP-1 cells. Our
data are consistent with a previous study showing higher sensitivity of BON-1 cells to BYL719
compared to QGP-1 cells [18]. Interestingly, colony formation was already suppressed at low
doses (IC50 1.3 μM in BON-1 and 1.8 μM in QGP-1 cells). The colony formation assay tests
every cell in the population for its ability to undergo “unlimited” division and determines
reproductive cell death after treatment with cytotoxic agents [50]. Therefore, colony formation
may also reflect interactions between tumor cells and its microenvironment and might even
better correlate with tumor growth in vivo than cell viability assays [51–53].
In all three NET cell lines investigated, BYL719 induced apoptosis associated with signifi-
cantly increased caspase 3 and. cleaved PARP. The highest sensitivity to BYL719 correlated
with strongest BYL719-induced apoptosis in BON-1 cells, followed by H727 cells and then
QGP-1 cells.
Moreover, BYL719 induced cell cycle arrest in the G0/G1-phase in all three cell lines. This
was consistent with a significant up-regulation of p27 in all cell lines investigated. The stron-
gest BYL719-mediated increase of p27 after 24 h treatment was found in BON-1 cells. A posi-
tive correlation of loss of p27 and aggressiveness as well as increased cell cycle progression of
gastroenteropancreatic NETs has previously been described [54].
After 24 h of BYL719 incubation, there was a significant decrease of activated DNA-damage
checkpoint marker Chk1 in all three cell lines. Interestingly, inhibition of Chk1 has shown
promising anti-cancer effects in vitro in a variety of p53 deficient human tumor cell lines
through induction of caspase-3/7 dependent apoptosis, and especially sensitized colon tumors
to chemotherapy in vivo [55, 56]. This may be an interesting additional effect in poorly differ-
entiated neuroendocrine carcinomas (NECs) which regularly bear p53 mutations [57]. The
observed significant decrease of the cell cycle inhibitor p21 may be due to PI3K/AKT inhibi-
tion by BYL719, since PI3K/AKT signaling increases p21 [58, 59]. The role of p21 has been a
controversal topic in the literature [60]. On the one hand, it is a cell cycle inhibitor leading to
cell cycle arrest and anti-proliferative signals. On the other hand, there is also evidence that
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Fig 8. The combination therapy with BYL719 plus everolimus strongly induced SSTR2 expression in
BON-1 and QGP-1 cells. Cells have been treated with 5 μM BYL719, 5 nM everolimus, or the combination of
both for 48h (A) or with 1 μM BYL719, 1 nM everolimus or the combination of both for 96h (B). SSTR2
expression was analyzed by Western Blot (A) and qPCR (B). Representative western blot of two replicates;
qPCR results are summarized from three independent experiments of three replicates. * p<0.05; ** p0.01;
*** p0.001.
https://doi.org/10.1371/journal.pone.0182852.g008
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p21 may inhibit apoptosis, promote tumor cell growth and cooperate with Chk1 to prevent
apoptosis during DNA replication fork stress [59–63]. Therefore, the observed decrease of p21
due to partial PI3K/AKT inhibition together with a Chk1 inhibition may also have pro-apo-
ptotic/anti-tumor effects.
Signaling pathways
Inhibition of PI3K/AKT/mTORC1/2 signaling. In all three cell lines, mTORC2-induced
PI3K/AKTSer473 signaling was significantly and partially, but not completely, inhibited by
BYL719 treatment, and the inhibition was stronger in BON-1 and QGP-1, compared to H727
cells. Similar data were found for PI3K/PDK1/AKTThr308 signaling with significant partial
inhibition in BON-1 and QGP-1 cells, but even activation in H727 cells after 24 h of treatment
with 10 μM BYL719. This suggests that, surprisingly, potent PI3K/AKT inhibition may not be
crucial for BYL719 efficacy in NET cells. This indicates potential non-selective effects of
BYL719 independent of the p110α subunit and the involvement of alternative signaling path-
ways, as discussed in detail below. Consistently, we could show only slight inhibitory effects of
a low dose of 1 μM BYL719 alone on cell viability, also arguing for non-selective effects of
BYL719 at higher doses.
Moreover, this indicates the potential importance of alternative PI3Kp110 catalytic subunit
isoforms in NET signaling. PI3K110α (the catalytic subunit of class I PI3K) has been consid-
ered as the only relevant catalytic subunit in the context of cancer associated mutations [64]
and has shown relevant anti-tumor potential in pancreatic NETs in vitro and in vivo [18, 65].
However, the other variants of the p110 catalytic subunit—β or δ—may be of importance and
promote sustained activity of PI3K/AKTSer473 and PI3K/AKTThr308 despite PI3K110α inhibi-
tion. The δ isoform of the p110 catalytic subunit of PI3K has already shown anti-tumor
potential in leukemia or in anaplastic thyroid carcinoma [66, 67]. The theory of potential
involvement of alternative PI3K subunit isoforms in NET signaling was supported by a much
stronger inhibitory effect of the panPI3K inhibitor BKM120, compared to BYL719, on BON-1
cell viability (IC20 BKM120 at 72h 0.5 μM vs. IC20 BYL719 at 72h 6.9 μM; IC50 BKM120 at 72h
1.2 μM vs. IC50 BYL719 at 72h not reached).
Interestingly, while we confirmed previous findings of a partial mTORC1 inhibition at
10 μM BYL719 in pancreatic NET cells [18], we noted that H727 cells showed more pro-
nounced mTORC1 inhibition accompanied by higher PI3K/AKT activity in response to
BYL719 treatment. Thus, our data might argue for a direct effect of BYL719 on mTORC1. In
this context, PI3K knock-down experiments would seem to be a reasonable procedure to
prove a direct impact of BYL719 on mTORC1 signaling and will be subject of further studies.
However, with our current study we were not able to confirm a direct effect of BYL719 on
mTORC1. BON-1 and QGP-1 cells behave very similarly with respect to the impact of BYL719
on PI3K/AKT/mTORC1 signaling although they showed different sensitivities. BON-1 cells
showed lower inhibition on PI3K/AKT signaling, compared to QGP-1 cells, and the lowest
inhibition of mTORC1 of all three cell lines, however, the highest sensitivity to BYL719 of all
three cell lines. Hence, the extent of PI3K/AKT/mTORC1 inhibition did not seem to correlate
with sensitivity to BYL719 in the different NET cell lines. This implicates another mechanism
of action different from PI3K/AKT/mTORC1 signaling responsible for the different cell line
sensitivities.
Inhibition of GSK3 in BON-1 and H727 cells, but not in QGP-1 cells at 24 h treat-
ment. The most evident difference between the three cell lines which might correlate with
different cell line sensitivities was found in GSK3 signaling. GSK3 is usually phosphorylated
and inhibited by the growth factor induced PI3K/AKT signaling pathway [46–48]. Hence,
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partial PI3K/AKT inhibition would be expected to lead to dephosphorylation/activation of
GSK3. However, unexpectedly, despite partial PI3K/AKT inhibition, BYL719 treatment led to
phosphorylation/inhibition of GSK3 in BON-1 and H727 cells with a significant and strongest
inhibition, especially of GSK3β in the most sensitive BON-1 cell line. Hence, our study sug-
gests an impact of BYL719 on GSK3 not directly linked to PI3K/AKT signaling. In contrast to
GSK3 inhibition in BON-1 and H727 cells, there was no phosphorylation/inhibition, but a mod-
est activation of GSK3 in the more resistant QGP-1 cells after BYL719 treatment.
The role of GSK3β in cancer has been discussed and remains controversial [46, 68]. Since
GSK3β induces phosphorylation and degradation of its downstream targets, and some GSK3β
substrates are key proteins for promoting cell survival, such as β-Catenin, Cyclin D1, eIF2B
and MYC [46, 68, 69], it was initially considered as a tumor suppressor. However, in contrast,
a tumor-promoting role of GSK3β has been reported in leukemia, glioblastoma, non-small cell
lung cancer, BON-1, insulinoma and H727 cells as well as medullary thyroid carcinoma cells
[70–75]. Accordingly, GSK3β inhibition has already shown anti-tumor potential with anti-
proliferative and pro-apoptotic effects in neuroblastoma, BON-1, H727 and medullary thyroid
carcinoma cells being accompanied by reduced expression of β-catenin and neuroendocrine
tumor markers [70, 71, 76, 77]. GSK3β inhibition also displayed anti-proliferative effects in
other tumor entities, including leukemia, non-small cell lung cancer, melanoma, prostate, pan-
creatic, colon and renal cell carcinoma [73, 75, 78–83]. Several studies have found that inhibi-
tion of GSK3β led to apoptosis through inhibition of NFκB, mitotic catastrophe in apoptosis-
resistant cells, and cycle arrest due to the increase of CDK inhibitors including p27 in vitro and
in vivo [46, 71, 84–88]. This is consistent with our findings of strongest GSK3 inhibition being
associated with highest sensitivity to BYL719 and strongest induction of apoptosis in BON-1,
compared to H727 and QGP-1 cells, after BYL719 treatment. One potential explanation for
this effect of BYL719 on GSK3 would be IGF1 receptor activation in all three cell lines to a dif-
ferent extent in response to BYL719 treatment. This theory, however, could not be supported
by our data, as discussed in detail below. A more detailed analysis of signaling effects is war-
ranted in novel primary cell lines and primary tumor cell cultures to understand differences in
signaling pathway alterations in NETs.
Compensatory activation of IGF1R. Svejda et al. have already reported a growth factor
mediated feedback loop in NET cells after mTORC1 inhibition [19], as we observed with
BYL719 in this study: we found a strong activation of IGF1R in all cell lines, which was already
seen at low doses of 1 μM BYL719 arguing for a specific effect of PI3Kα inhibition on IGF1R
signaling. In case of inappropriate strong mTORC1 activation, a negative feed-back effect on
IGFR signaling has previously been described [89]. Therefore, the observed activation of IGF1
receptor might be due to PI3K/mTORC1 inhibition and might be a potential compensatory
mechanism of the tumor cells. IGF1R activation seems to play an essential role in cancer cell
proliferation of different tumor cell entities including BON-1 cells [90–94].
On the other hand, IGF1R is known to phosphorylate/inhibit GSK3 [47]. Therefore, we
have tested a potential dependence of GSK3 phosphorylation on IGF1R signaling in our NET
cell lines through co-treatment of BYL719 with the specific IGF1R inhibitor NVP-AEW541.
Surprisingly, in BON-1 and H727 cells co-treatment with the specific IGF1R inhibitor
NVP-AEW541 even led to an enhanced (not reduced) GSK3 phosphorylation/inhibition,
compared to each drug separately, being associated with strongest IGF1R activation after com-
bination treatment in BON-1 and H727 cells; in QGP-1 cells, absent GSK3 phosphorylation/
inhibition, compared to the control, was accompanied by IGF1R inhibition after combination
treatment. NVP-AWE541 alone seemed to lead to a compensatory increase of total IGF1R
expression, potentially to compensate for the IGF1R inhibition, and thereby rendering cells
more sensitive to BYL719-induced IGF1R activation.
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However, the low baseline phosphorylation/activity of the IGF1R in BON1 and H727
cells might not have been sufficient to show the effects of specific IGF1R inhibition by
NVP-AEW541; moreover, another group stimulated their cells with IGF1 to demonstrate
the dependence of GSK3 phosphorylation on IGF1R activity in medulloblastoma cells [49],.
Therefore, we modified our experimental setting by using IGF1 stimulation. IGF1 stimula-
tion led to strong basal IGF1R phosphorylation/activity in all three cell lines, which could
then be clearly inhibited by NVP-AEW541 in all three cell lines. BYL719 alone led to strong
IGF1R phosphorylation/activation. However, despite clear IGF1R inhibition after combina-
tion treatment with NVP-AEW541 plus BYL719 in all three cell lines, the phosphorylation/
inhibition of GSK3 was even stronger (not blocked) after the combination treatment in
H727 cells and not changed in BON-1 and QGP-1 cells compared to single BYL719 treat-
ment. Therefore, according to these data, blockade of the IGF1R did not attenuate BYL719-
induced GSK3 phosphorylation. Due to optimizing our experimental design by IGF1 stimu-
lation according to a previously published experimental design [49], we have refuted our ini-
tial hypothesis of the dependence of BYL719-induced GSK3 phosphorylation on IGF1R
activation in BON1 and H727 cells. The mechanism through which BYL719 leads to GSK3
inhibition, thus still needs to be assessed and will be the subject of further studies. Essen-
tially, the IGF1R does not appear to mediate the effect of Byl719 on the phosphorylation of
GSK3.
Induction of cell re-differentiation in BON-1 and H727 cells, but not in
QGP-1 cells
BYL719 induced neuroendocrine differentiation in BON-1 and H727 cells as indicated by
increased expression of CgA (CHGA-), SSTR1- and SSTR2-mRNA; SSTR2 mRNA expression
was already significantly induced at a low dose of 1 μM BYL719 arguing for a specific effect of
PI3Kα inhibition on SSTR2-mRNA induction; in contrast, in QGP-1 cells, SSTR1 transcripts
were reduced, and CHGA and SSTR2 were unaffected.
Although CHGA-mRNA was found to be upregulated by BYL719, the compound did not
modulate CgA release from any of the cell lines studied. It was important to verify this, as Li
et al. have reported that the p110 catalytic subunit of PI3K negatively regulated neurotensin
secretion in BON-1 cells and that inhibition of p110 induced neurotensin release from these
cells [95]. Likewise, inhibition of the PI3K/PDK1/AKT pathway has been shown to upregulate
insulin secretion from pancreatic beta cells [96]. Potentiation of hormone hypersecretion in
NET patients would be considered an unwanted side effect that could limit the application of
this therapeutic principle. However, none of the three cell lines tested showed an increase of
CgA secretion under BYL719 treatment. In clinical practice, CgA is a marker for NETs in
terms of progression and changes in response to therapy, but has low sensitivity for diagnosis,
especially when the tumor burden is low. It tends to be higher in more differentiated tumors,
but there is considerable variability and in general it is not universally useful in determining
the degree of tumor differentiation [97].
In contrast, SSTR1/2 expression seems to be a more suitable marker for cell differentiation.
In general, almost 100% of low (G1) and intermediate grade (G2) NETs show SSTR expres-
sion, but high grade NETs and neuroendocrine carcinomas (NECs) (G3) show lesser expres-
sion. Hence, in less differentiated tumors SSTR expression is less frequent and SSTR density is
lower. Moreover, SSTR expression is less frequently seen in pancreatic than in gastrointestinal
tumors, as reviewed in [98]. Furthermore, SSTR2 expression positively correlated with better
prognosis In NET patients [99, 100]. Therefore, re-differentiation of tumor cells with an
increase of SSTR2 expression, as we observed after BYL719 and after BYL719/everolimus
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combination treatment (discussed below) in vitro, might lead to better differentiated tumors
and improve the prognosis of NET patients if transferable to humans. Moreover, the increased
SSTR1/2 expression upon BYL719 exposure could potentially be exploited for co-treatments
with somatostatin analogs. It also seems an interesting option to increase SSTR2 mediated
tracer uptake for imaging studies and peptide radioreceptor ligand therapy (PRRT). Interest-
ingly, SSTR5 seems to be differentially regulated compared to SSTR1 and SSTR2.
GSK3 inhibition might promote neuronal and pancreatic NET cell differentiation, as
described previously [101, 102]. Therefore, pronounced BYL719-induced inhibition of GSK3
in BON-1 and H727 cells may contribute to enhanced tumor cell differentiation; accordingly,
there was no inhibition, but even a slight activation of GSK3 in QGP-1 cells after 24 h BYL719
treatment associated with decreased cell differentiation.
Potentially, the BYL719-induced cell differentiation in BON-1 and H727 cells reflects re-
differentiation of tumor cells. A re-differentiation of thyroid carcinoma cells upon growth
arrest has been described previously [103]. Indeed, it has recently been reported, that treat-
ment of BON-1 cells with HDAC inhibitors can potently induce SSTR2 expression coinciding
with a profound proliferative arrest of the tumor cells [104].
Synergistic effect of BYL719 plus everolimus in QGP-1 cells
Although there was just a slight effect of a low dose of 1 μM BYL719 alone on BON-1 and no
relevant effect on QGP-1 cell viability, there was a synergistic effect of 1 μM BYL719 in
combination with the mTORC1-inhibitor everolimus (1 nM) in both cell lines. This may be
explained by additional everolimus-mediated mTORC1 inhibition rendering cells more sensi-
tive to BYL719, as previously reported for breast cancer cells [38], and BYL719-mediated pre-
vention of everolimus-induced AKT activation [16–18], as now shown in our cells. Moreover,
in another study on BON-1 cells (submitted data) we have shown a much stronger phosphory-
lation/inhibition of GSK3 after 72 h BYL719/everolimus combination treatment (by 2507%),
compared to each drug separately (by 195% and 298%, respectively). This again supports the
concept of combining targeted therapies in NETs, as previously shown to be effective: Com-
bined inhibition of mTORC1/2, PI3K/mTORC1/2, PI3K/mTORC1/2/ERK or EGFR/PI3K/
mTORC1 has shown promising anti-tumor potential in NETs in vitro [18, 28, 42, 45, 105]. Of
note implementing combination therapies could dramatically reduce the doses of single agent
treatment, as we observed synergistic effects already at subtherapeutic doses in monotherapy.
Moreover, since these synergistic effects already occurred at low doses of both drugs, the syn-
ergism might be a specific effect of simultaneous inhibition of the PI3Kα subunit by BYL719
and of mTORC1 by everolimus. Nevertheless, harmful side effects of combined treatments
should be evaluated in animal studies.
Furthermore, we found that the synergism of 1 μM BYL719 plus 1 nM everolimus was asso-
ciated with induction of cell re-differentiation and a significant increase of SSTR2 expression
in QGP-1 and BON-1 cells, compared to each drug separately, potentially sensitizing cells to
somatostatin analogs.
No synergistic or additive effect of the BYL719/everolimus combination was found in H727
cells. This is consistent with our finding of lower PI3K/AKTSer473 inhibition and even activa-
tion of PI3K/AKTThr308 associated with stronger mTORC1 inhibition by BYL719 alone in
H727 cells.
Conclusions
The selective PI3Kα inhibitor BYL719 significantly reduced cell viability and colony formation
in all NET cell lines investigated, with the highest sensitivity in BON-1, followed by H727 cells,
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and a much lower sensitivity in QGP-1 cells. The highest sensitivity of BON-1, followed by
H727 cells, might be due to stronger BYL719-induced apoptosis as a potential consequence of
GSK3 inhibition and tumor cell re-differentiation with significant SSTR1/2 up-regulation, in
contrast to lower apoptosis induction, absent GSK3 inhibition and absent re-differentiation in
QGP-1 cells [71, 72, 85, 101, 106, 107]. Thus, BYL719 may sensitize neuroendocrine tumor
cells to therapy with somatostatin analogs or PRRT, depending on the specific cell line. More-
over, BYL719/everolimus combination treatment showed synergistic effects in BON-1 and the
more resistant QGP-1 cells and might help to overcome everolimus or BYL719 resistance
through simultaneous AKT/mTORC1 inhibition. The BYL719/everolimus combination also
enhanced cell differentiation with significant SSTR2 up-regulation in BON-1 and QGP-1 cells,
compared to each drug separately.
In summary, our suggested hypothesis and our data indicate that BYL719 might be an
interesting novel therapeutic option for NETs, especially in combination with the approved
and promising somatostatin analogs or everolimus, which merits clinical therapeutic consider-
ation. However, our data also confirm the importance of individualized targeted therapies
depending on tumor entity.
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